A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

Sponsor

Astellas Pharma Global Development, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT02175433

Collaborator

(none)

Enrollment

Locations

Arms

60.5

Actual Duration (Months)

14.2

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AGS67E both without and with myeloid growth factor (GF) in subjects with refractory or relapsed lymphoid malignancies. Immunogenicity and anticancer activity of AGS67E will also be assessed.

Condition or Disease	Intervention/Treatment	Phase
Relapsed Lymphoid Malignancy Refractory Lymphoid Malignancy	Drug: AGS67E	Phase 1

Detailed Description

The dose escalation study will have two parts:

Dose Escalation of AGS67E without myeloid growth factor (GF)
Dose Escalation of AGS67E with myeloid growth factor (GF)

Subjects will be enrolled sequentially into dose cohorts starting with AGS67E without GF.

All subjects will receive a single 30 minute intravenous (IV) infusion of AGS67E once every three weeks. Subjects will continue treatment until disease progression, intolerability of AGS67E, investigator decision or consent withdrawal.

This dose escalation will first determine the maximum tolerated dose (MTD) of AGS67E without GF and then determine the MTD of AGS67E with GF. Once an MTD has been established, the study may enroll subjects into respective expansion cohorts of 12 subjects each at doses recommended by the data review team (DRT) (expansion cohort without GF and/or expansion cohort with GF).

During dose escalation, the Data Review Team will review cumulative unaudited data on an interim basis to review subject safety, recommend exploring additional doses and/or schedules, or the expansion of existing cohorts.

Study Design

Study Type:

Interventional

Actual Enrollment :

71 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies

Actual Study Start Date :

Oct 14, 2014

Actual Primary Completion Date :

Oct 29, 2019

Actual Study Completion Date :

Oct 29, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Dose Escalation of AGS67E 0.05 mg/kg Without GF Participants will receive 0.05 milligram per kilogram (mg/kg) AGS67E without growth factor (GF) by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Escalation of AGS67E 0.1 mg/kg Without GF Participants will receive 0.1 mg/kg AGS67E without GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Escalation of AGS67E 0.3 mg/kg Without GF Participants will receive 0.3 mg/kg AGS67E without GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Escalation of AGS67E 0.6 mg/kg Without GF Participants will receive 0.6 mg/kg AGS67E without GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Escalation of AGS67E 0.9 mg/kg Without GF Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Escalation of AGS67E 1.2 mg/kg Without GF Participants will receive 1.2 mg/kg AGS67E without GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Expansion of AGS67E 0.9 mg/kg Without GF Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Escalation of AGS67E 1.2 mg/kg With GF Participants will receive 1.2 mg/kg AGS67E with GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Escalation of AGS67E 1.5 mg/kg With GF Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Escalation of AGS67E 1.8 mg/kg With GF Participants will receive 1.8 mg/kg AGS67E with GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion
Experimental: Dose Expansion of AGS67E 1.5 mg/kg With GF Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.	Drug: AGS67E intravenous (IV) infusion

Outcome Measures

Primary Outcome Measures

Incidence and nature of adverse events [up to 34 months]
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Concentration at the end of infusion (CEOI) [Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months]
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax) [Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months]
Pharmacokinetic parameter for Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax) [Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months]
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-21) [Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months]
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Terminal or apparent terminal half-life (t1/2) [Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months]
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Systemic clearance (CL) [Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months]
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Volume of distribution at steady state (Vss) [Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months]

Secondary Outcome Measures

Incidence of Anti-Drug Antibody (ADA) formation to the fully human monoclonal antibody (AGS67C) and antibody-drug conjugate (AGS67E) [Up to 34 months]
Incidence of tumor response [Up to 34 months]
Tumor response is defined as either a complete response (CR) or partial response (PR)
Objective response rate (ORR) [Up to 34 months]
ORR for a cohort is defined as the percentage of subjects who experience a best response of either complete response (CR) or partial response (PR) in that cohort.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Refractory or relapsed chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) or non-Hodgkin lymphoma (NHL) (including those of T cell origin)
Eastern Cooperative Oncology Group performance score (ECOG) ≤ 2
Negative pregnancy test (women of childbearing potential)
Hematologic function, as follows (no platelet transfusion within 2 weeks and no RBC transfusion within 4 days before the first dose of study drug)
Absolute neutrophil count (ANC) ≥ 1,000/μL
Platelets ≥ 75,000/μL
Hemoglobin ≥ 8 g/dL (may be transfused ≥ 5 days)
Renal function: serum creatinine ≤ 2.0 mg/dL and estimated creatinine clearance of ≥ 45 mL/min by the Cockcroft-Gault equation
Direct bilirubin ≤ 1.5 x upper limit of normal (ULN)
Serum albumin ≥ 2.5 g/dL
Aspartate aminotransferase (AST) ≤ 1.5 x ULN unless there is hepatic involvement, then 3 x ULN
Alanine aminotransferase (ALT) ≤ 1.5 x ULN unless there is hepatic involvement, then 3 x ULN
Sexually active fertile subjects, and their partners, must agree to use medically accepted double-barrier methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study and at least 6 weeks after termination of study therapy

Exclusion Criteria:

Preexisting sensory and/or motor neuropathy Grade ≥ 2
Small molecule therapy, radiotherapy, immunotherapy, monoclonal antibodies, or chemotherapy within 2 weeks before first dose of study drug
Radioimmunotherapy within 4 weeks before first dose of study drug
Use of any investigational drug (including marketed drugs not approved for this indication) within 14 days prior to the first dose of study drug
Any P-gp inducers/inhibitors or strong CYP3A inhibitors within 2 weeks before the first dose of study drug (See Appendix F for list of excluded drugs)
Anti Graft-Versus-Host Disease (GVHD) therapy within 12 weeks before the first dose of study drug
Platelet transfusion within 2 weeks and RBC transfusion within 4 days before the first dose of study drug
Known central nervous system (CNS) disease
History of other primary malignancy (including myeloid malignancy, e.g., myelodysplastic syndrome), unless
Curatively resected nonmelanomatous skin cancer
Other malignancy curatively treated with no known active disease present and no systemic treatment administered for 3 years before the first dose of study drug
Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of the first dose of study drug, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient medication
Women who are pregnant or lactating
Known HIV positive or AIDS
Positive Hepatitis B surface antigen test
Decompensated liver disease as evidenced by clinically significant ascites refractory to diuretic therapy, hepatic encephalopathy, or coagulopathy
Known sensitivity to any of the components of the investigational product AGS67E:
AGS67E
L-Histidine
α-trehalose dihydrate or
polysorbate 20
History of thromboembolic events (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) ≤ 2 weeks before the first dose of study drug and/or clinical diffuse intravascular coagulation (DIC)
Active infection requiring treatment ≤7 days before the first dose of study drug
Condition or situation which may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study
Any medical, psychiatric, addictive or other disorder which compromises the ability of the subject to give written informed consent and/or to comply with procedures.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Site US0006	Duarte	California	United States	91010
2	Site US0002	Stanford	California	United States	94305
3	Site US0004	Fairway	Kansas	United States	66205
4	Site US0001	New York	New York	United States	10019
5	Site CA0005	Vancouver	British Columbia	Canada	V5Z 4E6